FDA Clearance Tracker · P220029-S001
Optilume BPH Catheter System
Last checked: Nov 20, 2026Latest source record: Aug 25, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Aug 25, 2023
Approved
Time to decision
29 days
Received Jul 27, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P220029-S001
- Device name
- Optilume BPH Catheter System
- Applicant
- Urotronic, Inc.
- Applicant location
- Minneapolis, MN
- Received
- Jul 27, 2023
- Decided
- Aug 25, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P220029
Device type
- Device class
- Class III
- Specialty
- GI, Urology & NephrologyUrology
FDA's approval statement
As written in FDA's record.
Approval of the protocol for the post-approval study (PAS) protocol.
Source documents
Other decisions for Urotronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K250910 · Decided May 22, 2025 · 57 days after receipt
Device type: Dilator, Catheter, Ureteral (EZN) · GI, Urology & Nephrology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.